Jazz Pharmaceuticals PLC (JAZZ) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Jazz Pharmaceuticals PLC

NASDAQ | JAZZ

120.82

USD

-5.62 (-4.44%)

AT CLOSE (AS OF Apr 3, 2025)

$7.7B

MARKET CAP

14.62

P/E Ratio

8.65

EPS

$148

52 Week High

$99

52 Week Low

LIFE SCIENCES

Sector

JAZZ Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

JAZZ Technicals

Tags:

JAZZ Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	$1.9B
Total Revenue	$3.8B
Cost Of Revenue	$2B
Costof Goods And Services Sold	$436M
Operating Income	$579M
Selling General And Administrative	$1.3B
Research And Development	$869M
Operating Expenses	$2.8B
Investment Income Net	$65M
Net Interest Income	-$33M
Interest Income	-
Interest Expense	$33M
Non Interest Income	$3.8B
Other Non Operating Income	-
Depreciation	$30M
Depreciation And Amortization	$609M
Income Before Tax	$295M
Income Tax Expense	-$120M
Interest And Debt Expense	$33M
Net Income From Continuing Operations	$415M
Comprehensive Income Net Of Tax	$698M
Ebit	$579M
Ebitda	$937M
Net Income	$415M

Revenue & Profitability

Earnings Performance

JAZZ Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$11B
Total Current Assets	$3.4B
Cash And Cash Equivalents At Carrying Value	$1.5B
Cash And Short Term Investments	$1.5B
Inventory	$597M
Current Net Receivables	$706M
Total Non Current Assets	$7.8B
Property Plant Equipment	$165M
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$7.2B
Intangible Assets Excluding Goodwill	$5.4B
Goodwill	$1.8B
Investments	$120M
Long Term Investments	-
Short Term Investments	$120M
Other Current Assets	$321M
Other Non Current Assets	$67M
Total Liabilities	$7.7B
Total Current Liabilities	$1.5B
Current Accounts Payable	$103M
Deferred Revenue	-
Current Debt	$605M
Short Term Debt	$624M
Total Non Current Liabilities	$6.1B
Capital Lease Obligations	$5M
Long Term Debt	$5.7B
Current Long Term Debt	$605M
Long Term Debt Noncurrent	$5.1B
Short Long Term Debt Total	$5.7B
Other Current Liabilities	$774M
Other Non Current Liabilities	$105M
Total Shareholder Equity	$3.7B
Treasury Stock	-
Retained Earnings	$879M
Common Stock	$6K
Common Stock Shares Outstanding	$62M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	$1.1B
Payments For Operating Activities	$532M
Proceeds From Operating Activities	-
Change In Operating Liabilities	$4.9M
Change In Operating Assets	$207M
Depreciation Depletion And Amortization	$30M
Capital Expenditures	$24M
Change In Receivables	$52M
Change In Inventory	$13M
Profit Loss	$415M
Cashflow From Investment	-$163M
Cashflow From Financing	-$305M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	$270M
Payments For Repurchase Of Equity	$270M
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-$223M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$415M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	$1.9B
Total Revenue	$3.8B
Cost Of Revenue	$2B
Costof Goods And Services Sold	$436M
Operating Income	$579M
Selling General And Administrative	$1.3B
Research And Development	$869M
Operating Expenses	$2.8B
Investment Income Net	$65M
Net Interest Income	-$33M
Interest Income	-
Interest Expense	$33M
Non Interest Income	$3.8B
Other Non Operating Income	-
Depreciation	$30M
Depreciation And Amortization	$609M
Income Before Tax	$295M
Income Tax Expense	-$120M
Interest And Debt Expense	$33M
Net Income From Continuing Operations	$415M
Comprehensive Income Net Of Tax	$698M
Ebit	$579M
Ebitda	$937M
Net Income	$415M

JAZZ Profile

Jazz Pharmaceuticals PLC Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$101.80	-7.81%	$2.68T	334,149,797
INTC	$22.43	2.05%	$95.85B	240,924,655
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.42	84.14%	$4.04M	177,332,811
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

JAZZ $120.82 (-4.44%) Quote details